Partnering

Leading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine Innovation

Retrieved on: 
Thursday, March 14, 2024
Molecule, Learning Technology Partners, Personalized medicine, Organization, Conference, Innovation, Biotechnology, AstraZeneca, Partnering, Convention, Virtual humans, Data science, Drug discovery, RWE, Bias, Shape, Social media, Stargate Atlantis, RWD, Transformation, Bristol Myers Squibb, Digital twin, Student, LDN, Investment, Vacuum, RDN, Water, Machine learning, MD Anderson Cancer Center, Pharmaceutical industry

BOSTON, March 14, 2024 /PRNewswire/ -- Life science innovation doesn't happen in a vacuum. It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.

Key Points: 
  • It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.
  • From April 15-17, more than 3,000 pharmaceutical, biotechnology and IT leaders will gather for the 23rd annual Bio-IT World Conference & Expo in Boston to put this model into action.
  • "Precision medicine is at a tipping point as both scientific and computing capabilities explode," said Cindy Crowninshield, RDN, LDN, Executive Event Director.
  • This year, the Bio-IT World conference will focus on how to keep the creative pipeline flowing by bringing rising scientists into the fold.

EQS-News: BIO-Europe Spring® 2024 is only a few days away

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Merck, Partnering, SVP, Life, ESC, Merck Group, Business development, University, Sustainable business, IQVIA, CSO, Ferrer, Partnership

Munich, Germany – March 7, 2024.

Key Points: 
  • Munich, Germany – March 7, 2024.
  • EBD Group is thrilled to welcome the global biopharma community to Barcelona, Spain, March 18–20.
  • Over 3,700 delegates are looking forward to meeting one-to-one to elevate life science partnerships globally.
  • The session “For a greener globe: Biopharma’s journey to a sustainable future” is scheduled for the afternoon on Monday, March 18.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, EDT, Head, CD3, SAN, Investigational New Drug, Cancer, EGFR, Research, Biotechnology, Partnering, TCE, Epithelial cell adhesion molecule, Investment, Melanoma, FDA, Amgen, Therapeutic index, Food, Camptothecin, Gastrointestinal tract, Bladder cancer, Drug discovery, CRC, ADC, Bristol Myers Squibb, BMS, Safety, Kidney, Cytokine, Webcast, Tumor microenvironment, PDT, Patient, Workforce, IND, Trial of the century, Colorectal cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Amprius Sets March 2024 Events Schedule

Retrieved on: 
Monday, March 4, 2024
Other Energy, Technology, Batteries, Manufacturing, Energy, Other Manufacturing, Hardware, Booth, Partnering, Mobile phone

Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced its schedule for March appearances and activities.

Key Points: 
  • Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, today announced its schedule for March appearances and activities.
  • Event Details: Amprius CTO Dr. Ionel Stefan will be presenting on Wednesday, March 13, at 3:40 p.m. CT/1:40 p.m. PT.
  • Event Details: Amprius CTO Dr. Ionel Stefan will be presenting on Friday, March 15th, at 8:30 a.m. ET/5:30 a.m. PT.
  • Amprius CEO Dr. Kang Sun will appear on the Emerging Battery Technologies panel discussion at 2:00 p.m. ET/11:00 a.m. PT.

Minister Guilbeault calls for an ambitious plastics treaty at the United Nations Environment Assembly in Kenya

Retrieved on: 
Friday, March 1, 2024
Nature, COP29, COP16, Partnering, The Honourable, Climate, Biodiversity loss, South Korea, Excellency, Biodiversity, Government, Climate change, Conference, Plastic, International development, United Nations, Guilbeault, Environment, High Ambition Coalition, Property management

The Honourable Steven Guilbeault, Minister of Environment and Climate Change, wrapped up Canada's participation in the sixth session of the United Nations Environment Assembly (UNEA-6) in Nairobi, Kenya.

Key Points: 
  • The Honourable Steven Guilbeault, Minister of Environment and Climate Change, wrapped up Canada's participation in the sixth session of the United Nations Environment Assembly (UNEA-6) in Nairobi, Kenya.
  • Minister Guilbeault held meetings with environment ministers in Africa, as well as civil society, business leaders, and youth on advancing progress on climate, biodiversity, and the elimination of plastic pollution.
  • I'm encouraged by the collaboration demonstrated at the sixth session of the United Nations Environment Assembly, especially toward developing the global agreement on plastic pollution.
  • – The Honourable Ahmed Hussen, Minister of International Development
    At the sixth session of the United Nations Environment Assembly, Minister Guilbeault, on behalf of the Honourable Ahmed Hussen, Minister of International Development, announced the allocation of $107 million to Canada's Partnering for Nature initiative.

Marine Layer And Trashie Partner On Clothing Recycling Program

Retrieved on: 
Thursday, February 15, 2024
EPA, Textile, Environment, SAN, Clothing, Recycling, CO2, Partnering, Marine layer, DTC, Partnership

NEW YORK and SAN FRANCISCO, Feb. 15, 2024 /PRNewswire/ -- Marine Layer, the San Francisco-based apparel brand, and Trashie, the recycling and rewards platform, are excited to announce their partnership to bring an expanded clothing recycling service to customers. The partnership unites Marine Layer's Re-Spun program, which launched in 2018 to give t-shirts a second life, with Trashie's Take Back Bag program, which gives customers an easy way to recycle unwanted clothing, accessories, and linens from any brand in almost any condition.

Key Points: 
  • NEW YORK and SAN FRANCISCO, Feb. 15, 2024 /PRNewswire/ -- Marine Layer , the San Francisco-based apparel brand, and Trashie , the recycling and rewards platform, are excited to announce their partnership to bring an expanded clothing recycling service to customers.
  • Leveraging Trashie's recycling platform, Marine Layer will be able to increase recycling rates by an estimated 5x while tracking detailed impact metrics.
  • "Marine Layer and the team at Trashie have been pioneering circularity for years," said Michael Natenshon, founder & CEO of Marine Layer.
  • "Our partnership with Marine Layer allows us to collectively make a tangible impact on the environment and reshape how people perceive clothing recycling."

Hero Digital Helps Calix Create and Launch New Website on Adobe Experience Manager

Retrieved on: 
Tuesday, February 13, 2024
Adobe, AEM, BSP, Partnering, Content, Google Lighthouse, Salesforce Marketing Cloud, Partnership, Online shopping

CHICAGO, Feb. 13, 2024 /PRNewswire/ -- Hero Digital, an award-winning customer experience transformation company, managed the development and launch of Calix's new online experience: Calix.com. Designed and built by the Hero Digital team on Adobe Experience Manager, the new experience helps Calix modernize the world, one community at a time. 

Key Points: 
  • Designed and built by the Hero Digital team on Adobe Experience Manager, the new experience helps Calix modernize the world, one community at a time.
  • "We're very proud to partner with Calix to relaunch Calix.com on AEM," said Jay Dettling, CEO of Hero Digital.
  • Partnering closely with Calix, Hero Digital redesigned its corporate website to represent a new digital expression for the brand.
  • Using Adobe Experience Manager (AEM), Hero Digital's team redesigned the entire Calix website.

MDB Capital Holdings Issues Annual Letter to Shareholders

Retrieved on: 
Wednesday, January 31, 2024
Partnering, Family, DTC, Season, Failure, Pacific Ocean, Public, MDBH, Sanofi, University, Athlete, Splenic infarction, FDA, MDB, Inflammation, Publication, Investment, Type 1, Entrepreneurship, Bloomberg, Physician, Insulin, IP, Culture, Letter, Fox Business, Holiday, Probability, Invention, Sales

Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.

Key Points: 
  • Addison, TX, Jan. 31, 2024 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform with the objective of growing the public venture marketplace and optimizing the way meaningful technologies are financed and built, today released its annual letter to shareholders from its CEO and Co-Founder, Christopher Marlett.
  • To the Shareholders of MDB Capital Holdings, LLC:
    Welcome to our first annual letter, which I plan to send every January to reflect on the past year and how what we learned will shape our plans for the following year.
  • Undervalued Public Companies: We identify and partner with more mature public companies with undervalued technologies that possess significant leadership potential.
  • We then combine that with our community of experienced investors that commit not only their monetary capital, but their intellectual capital to help each company succeed.

DENSO Works with ESG to Reduce Carbon, Improve Sustainability in Battle Creek, Michigan, Operations

Retrieved on: 
Tuesday, January 30, 2024
Engineering, Account executive, Wind, Mind, Eco, DENSO, ESG, Consumer, Carbon, Partnering, Solar energy, Compressed air, Consumers Energy, Renewable energy

SOUTHFIELD, Mich., Jan. 30, 2024 /PRNewswire/ -- DENSO, a leading mobility supplier, is working with Energy Systems Group (ESG) to increase the sustainability of operations at its thermal manufacturing facility in Battle Creek, Michigan. Through the collaboration, the leading energy solutions company is replacing and updating compressed air systems at the DENSO site, enhancing its energy efficiency and climate friendliness.

Key Points: 
  • Through the collaboration, the leading energy solutions company is replacing and updating compressed air systems at the DENSO site, enhancing its energy efficiency and climate friendliness.
  • In summer 2024, when updates are expected to be complete, the new systems will begin to help DENSO remove nearly 3,000 tons of carbon dioxide annually from the thermal facility's operations.
  • In April 2023, the Battle Creek thermal facility alongside other Michigan businesses joined the Consumers Energy Business Renewable Energy Program.
  • If interested in growing your career at an automotive and sustainability leader, go here .

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Retrieved on: 
Thursday, January 4, 2024
Camptothecin, Therapeutic index, Immunotherapy, Lung cancer, Cytokine, Drug discovery, CRC, Tumor microenvironment, Amgen, Biotechnology, IND, Kidney, Bladder cancer, Research, Colorectal cancer, EGFR, MSS, Epithelial cell adhesion molecule, Melanoma, SAN, Therapy, Cancer, Head, Neoplasm, Gastrointestinal tract, Toxicity, Ipilimumab, Patient, Bristol Myers Squibb, Partnering, ADC, NSCLC, CD3, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.
  • “With INDs recently filed for wholly-owned programs, CX-2051 and CX-801, and continued progress in dose escalation with our Probody® T-Cell engager, CX-904, CytomX is well positioned as we enter 2024.
  • CytomX has a consistent track record of forming new strategic research and development alliances and achieving preclinical research and clinical milestones.
  • Cash runway is projected to the second half of 2025, excluding any potential milestones from existing collaborations or new business development.